Molecular mechanisms of Buqing granule for the treatment of diabetic retinopathy: Network pharmacology analysis and experimental validation

Table 1 Primer information

Gene	Sequence	Product length (bp)
TP53	F:5’-GGCTCCGACTATACCACTATCCAC-3’	129
	R:5'GTCCCGTCCCAGAAGATTCCC-3'
AKT1	F:5’AACTTCTCAGTGGCACAATGTCAG-3’	71
	R:5’CAGCGGATGATGAAGGTGTTGG-3’
c-Jun	F:5'TCTACGACGATGCCCTCAACG-3'	99
	R:5’GGTTCAAGGTCATGCTCTGCTTC-3’
Caspase-3	F:5’CGGTATTGAGACAGACAGTGGAAC-3’	90
	R:5’GCGGTAGAGTAAGCATACAGGAAG-3’
MAPK1	F:5'CTTCCAACCTCCTGCTGAACAC-3'	117
	R:5’GCGTGGCTACATACTCTGTCAAG-3’
MAPK3	F:5’CGCATCACAGTAGAGGAAGCAC-3’	72
	R:5’CACTGGTTCATCTGTCGGATCATAG-3’
GAPDH	F:5’-CAAGTTCAACGGCACAGTCAAGG-3’	123
	R:5’-ACATACTCAGCACCAGCATCACC-3’